These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 17348492)

  • 1. Lipid-lowering therapy--benefits and risks.
    Shechter M
    Isr Med Assoc J; 2007 Feb; 9(2):133; author reply 133-4. PubMed ID: 17348492
    [No Abstract]   [Full Text] [Related]  

  • 2. Lipid-lowering therapy--benefits and risks.
    Abinader EG
    Isr Med Assoc J; 2007 Feb; 9(2):132-3; author reply 133-4. PubMed ID: 17354321
    [No Abstract]   [Full Text] [Related]  

  • 3. Intensive lipid-lowering therapy: obvious benefits, possible risks.
    Zimlichman E; Szyper-Kravitz M; Katz U; Shoenfeld Y
    Isr Med Assoc J; 2006 Dec; 8(12):890-1. PubMed ID: 17214117
    [No Abstract]   [Full Text] [Related]  

  • 4. Choice of lipid-regulating drugs.
    Med Lett Drugs Ther; 2001 May; 43(1105):43-8. PubMed ID: 11378632
    [No Abstract]   [Full Text] [Related]  

  • 5. Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials.
    Kashani A; Sallam T; Bheemreddy S; Mann DL; Wang Y; Foody JM
    Am J Cardiol; 2008 Jun; 101(11):1606-13. PubMed ID: 18489938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. After the failure of ENHANCEd cholesterol lowering in familial hypercholesterolemia, SEAS of problems with ezetimibe.
    Mascitelli L; Ravnskov U; Pezzetta F; Goldstein MR
    Angiology; 2009; 60(1):127-8; author reply 129-30. PubMed ID: 19049996
    [No Abstract]   [Full Text] [Related]  

  • 7. Myopathy caused by a combination rosuvastatin and fenofibrate.
    Dedhia V; Munsi SC
    J Assoc Physicians India; 2007 Feb; 55():152-3. PubMed ID: 17571748
    [No Abstract]   [Full Text] [Related]  

  • 8. Myotoxicity associated with lipid-lowering drugs.
    Baer AN; Wortmann RL
    Curr Opin Rheumatol; 2007 Jan; 19(1):67-73. PubMed ID: 17143099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antilipemic therapy and rhabdomyolysis].
    Paragh G; Balogh Z; Romics L
    Orv Hetil; 2003 Mar; 144(11):515-20. PubMed ID: 12731338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experts confirm statins' safety but advise caution with certain patients.
    Levenson D
    Rep Med Guidel Outcomes Res; 2002 Jul; 13(13):1-2, 5. PubMed ID: 12515256
    [No Abstract]   [Full Text] [Related]  

  • 11. Worsening myopathy associated with ezetimibe in a patient with McArdle disease.
    Perez-Calvo J; Civeira-Murillo F; Cabello A
    QJM; 2005 Jun; 98(6):461-2. PubMed ID: 15897216
    [No Abstract]   [Full Text] [Related]  

  • 12. Statin use and its association with musculoskeletal symptoms--a cross-sectional study in primary care settings.
    Mosshammer D; Lorenz G; Meznaric S; Schwarz J; Muche R; Mörike K
    Fam Pract; 2009 Apr; 26(2):88-95. PubMed ID: 19233960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rosuvastatin--a new lipid-lowering drug.
    Med Lett Drugs Ther; 2003 Oct; 45(1167):81-3. PubMed ID: 14534507
    [No Abstract]   [Full Text] [Related]  

  • 14. Ask the doctor. I have tried all of the statin drugs to lower my cholesterol, but each one has caused severe muscle pain. Are there any non-statin medications I could try using to lower my cholesterol?
    Lee T
    Harv Heart Lett; 2010 Aug; 20(12):8. PubMed ID: 20812395
    [No Abstract]   [Full Text] [Related]  

  • 15. Lipid management in the geriatric patient.
    Nair AP; Darrow B
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):185-206. PubMed ID: 19217519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [HMG-CoA reductase inhibitors in therapy of disorders of lipid metabolism].
    Windler E; Greten H
    Internist (Berl); 1993 Dec; 34(12):1107-14. PubMed ID: 8106206
    [No Abstract]   [Full Text] [Related]  

  • 17. [Myopathy with rhabdomyolysis as an adverse effect of simultaneous treatment with cerivastatin and gemfibrozil].
    Huić M; Anić B; Cikes N; Bosnić D; Sentić M; Markeljević J; Mayer M; Pazanin L
    Lijec Vjesn; 2002; 124(3-4):73-6. PubMed ID: 18956824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
    Hou R; Goldberg AC
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy.
    Polonsky TS; Davidson MH
    Am J Cardiol; 2008 Apr; 101(8A):27B-35B. PubMed ID: 18375238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatal and widespread skeletal myopathy confirmed morphologically years after initiation of simvastatin therapy.
    Boltan DD; Lachar W; Khetan A; Bouffard JP; Roberts WC
    Am J Cardiol; 2007 Apr; 99(8):1171-6. PubMed ID: 17437752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.